Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Jhaveri KL, et al. Among authors: ma w. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283132 Free PMC article.
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. Among authors: ma w. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. Modi S, et al. Among authors: ma w. Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558407 Clinical Trial.
Bevacizumab in advanced endometrial cancer.
Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, Lakhman Y, Makker V. Rubinstein MM, et al. Among authors: ma w. Gynecol Oncol. 2021 Jun;161(3):720-726. doi: 10.1016/j.ygyno.2021.04.016. Epub 2021 Apr 22. Gynecol Oncol. 2021. PMID: 33894982 Free PMC article.
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA 3rd, Ma W, Espino K, Gordhandas S, Yeoshoua E, Ehmann S, Zhou Q, Iasonos A, Abu-Rustum NR, Aghajanian C, Green AK, Rubinstein MM, Makker V. Zammarrelli WA 3rd, et al. Among authors: ma w. Gynecol Oncol. 2023 Nov;178:27-35. doi: 10.1016/j.ygyno.2023.09.010. Epub 2023 Sep 23. Gynecol Oncol. 2023. PMID: 37748268
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM, Filippova OT, Cowan RA, Lakhman Y, Sarasohn DM, Nikolovski I, Torrisi JM, Ma W, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Chi DS, Long Roche K. Straubhar AM, et al. Among authors: ma w. Gynecol Oncol. 2020 Sep;158(3):608-613. doi: 10.1016/j.ygyno.2020.05.041. Epub 2020 Jun 6. Gynecol Oncol. 2020. PMID: 32518012 Free PMC article.
HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iaosonos A, Tessier-Cloutier B, Ross DS, Troso-Sandoval T, Reis-Filho JS, Abu-Rustum N, Zhang Y, Ellenson LH, Weigelt B, Makker V, Chui MH. Shen S, et al. Among authors: ma w. Mod Pathol. 2023 Nov;36(11):100299. doi: 10.1016/j.modpat.2023.100299. Epub 2023 Aug 7. Mod Pathol. 2023. PMID: 37558129
12,563 results
You have reached the last available page of results. Please see the User Guide for more information.